PTC Historical Cash Flow
| PTCT Stock | USD 45.11 0.90 1.96% |
Analysis of PTC Therapeutics cash flow over time is an excellent tool to project PTC Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Cash of 330.1 M or Stock Based Compensation of 137.8 M as it is a great indicator of PTC Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining PTC Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether PTC Therapeutics is a good buy for the upcoming year.
PTC |
About PTC Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in PTC balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which PTC's non-liquid assets can be easily converted into cash.
PTC Therapeutics Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by PTC Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of PTC Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in PTC Therapeutics financial statement analysis. It represents the amount of money remaining after all of PTC Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from PTC Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into PTC Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.At this time, PTC Therapeutics' Depreciation is comparatively stable compared to the past year. Other Non Cash Items is likely to gain to about 158.9 M in 2024, whereas Change In Working Capital is likely to drop (4.2 M) in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Other Non Cash Items | 128.3M | 82.8M | 151.3M | 158.9M | Depreciation | 64.1M | 128.8M | 236.6M | 248.4M |
PTC Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
PTC Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PTC Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Capital Expenditures | 45.4M | 56.0M | 85.3M | 152.5M | 120.6M | 126.6M | |
| Total Cash From Financing Activities | 613.2M | 668.7M | 20.9M | 168.0M | 646.4M | 678.7M | |
| Change To Liabilities | 40.5M | 66.9M | 41.6M | 23.0M | 26.4M | 25.6M | |
| End Period Cash Flow | 295.5M | 216.3M | 197.2M | 295.9M | 610.3M | 640.8M | |
| Change In Cash | 126.0M | (79.2M) | (19.1M) | 98.7M | 314.4M | 330.1M | |
| Stock Based Compensation | 42.1M | 70.3M | 103.5M | 110.3M | 131.2M | 137.8M | |
| Free Cash Flow | (144.1M) | (250.0M) | (336.7M) | (509.1M) | (279.0M) | (265.1M) | |
| Change In Working Capital | 20.4M | 36.9M | (23.8M) | (85.3M) | (4.0M) | (4.2M) | |
| Begin Period Cash Flow | 169.5M | 295.5M | 216.3M | 197.2M | 295.9M | 310.7M | |
| Total Cashflows From Investing Activities | (387.2M) | (561.5M) | 219.2M | 290.2M | 333.7M | 350.4M | |
| Other Cashflows From Financing Activities | 301.1M | 686.8M | 23.1M | (30.8M) | 947.8M | 995.2M | |
| Depreciation | 32.2M | 84.9M | 64.1M | 128.8M | 236.6M | 248.4M | |
| Other Non Cash Items | 49.4M | 46.1M | 128.3M | 82.8M | 151.3M | 158.9M | |
| Total Cash From Operating Activities | (98.6M) | (194.1M) | (251.3M) | (356.7M) | (158.4M) | (166.3M) | |
| Change To Account Receivables | 11.5M | (10.5M) | (45.0M) | (48.5M) | (1.5M) | (1.6M) | |
| Net Income | (251.6M) | (438.2M) | (523.9M) | (559.0M) | (626.6M) | (595.3M) | |
| Sale Purchase Of Stock | 345.6M | 103.6M | 23.1M | 71.1M | 64.0M | 89.2M | |
| Change To Inventory | (3.5M) | 1.8M | 1.8M | (6.7M) | (8.2M) | (7.8M) | |
| Investments | (341.8M) | (505.6M) | 304.5M | 442.6M | (49.9M) | (47.4M) | |
| Change Receivables | 11.5M | (10.5M) | (45.0M) | (48.5M) | (43.6M) | (41.4M) | |
| Cash And Cash Equivalents Changes | 126.0M | (86.9M) | (11.3M) | 101.5M | 116.7M | 122.5M | |
| Cash Flows Other Operating | (24.4M) | 75.8M | 54.7M | (11.7M) | (13.5M) | (12.8M) | |
| Other Cashflows From Investing Activities | (31.7M) | (38.1M) | (57.1M) | (120.4M) | (108.4M) | (103.0M) | |
| Change To Netincome | 97.8M | 65.1M | 230.4M | 113.8M | 130.8M | 79.0M | |
| Change To Operating Activities | (13.1M) | (17.2M) | (22.2M) | (68.7M) | (61.8M) | (58.7M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.